Discovery of Selective and Orally Bioavailable Protein Kinase Cθ (PKCθ) Inhibitors from a Fragment Hit
Dawn M. George, Eric C. Breinlinger, Michael Friedman et al. · Journal of Medicinal Chemistry · 2014
Protein kinase Cθ (PKCθ) regulates a key step in the activation of T cells. On the basis of its mechanism of action, inhibition of this kinase is hypothesized to serve as an effective therapy for autoimmune diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis. Herein, the discovery of a small molecule PKCθ inhibitor is described, starting from a fragment hit 1 and advancing to compound 41 through the use of structure-based drug design. Compound 41 demonstrates excellent in vitro activity, good oral pharmacokinetics, and efficacy in both an acute in vivo mechanistic model and a chronic in vivo disease model but suffers from tolerability issues upon chronic dosing.
Cited by 45 works. doi:10.1021/jm500669m
Authors
- Dawn M. George
- Eric C. Breinlinger
- Michael Friedman
- Yang Zhang
- Jianfei Wang
- M.A. Argiriadi
- Pratima Bansal‐Pakala
- Martine Barth
- David B. Duignan
- Prisca Honoré
- Qingyu Lang
- Scott W. Mittelstadt
- Dominique Potin
- Lian Rundell
- Jeremy J. Edmunds
References
- Current Protocols in Immunology
- PKC-θ is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes
- PKC-α regulates cardiac contractility and propensity toward heart failure
- Reprogramming the Immune System for Peripheral Tolerance with CD4 and CD8 Monoclonal Antibodies
- Protein Kinase C θ Affects Ca2+ Mobilization and NFAT Activation in Primary Mouse T Cells
- Protein Kinase C-θ Mediates Negative Feedback on Regulatory T Cell Function
- PKC and the control of localized signal dynamics
- The PKC inhibitor AEB071 may be a therapeutic option for psoriasis
- Protein Kinase C θ Is Critical for the Development of In Vivo T Helper (Th)2 Cell But Not Th1 Cell Responses
- Resistance to Experimental Autoimmune Encephalomyelitis and Impaired IL-17 Production in Protein Kinase Cθ-Deficient Mice